Modality
mRNA
MOA
USP1i
Target
PSMA
Pathway
JAK/STAT
PAHGAEoE
Development Pipeline
Preclinical
Oct 2017
→ Mar 2026
PreclinicalCurrent
NCT08880726
2,417 pts·EoE
2022-08→TBD·Recruiting
NCT05664978
1,034 pts·PAH
2017-10→2026-03·Recruiting
3,451 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-162w agoInterim· PAH
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Preclinical
Recruit…
Preclinical
Recruit…
Catalysts
Interim
2026-03-16 · 2w ago
PAH
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08880726 | Preclinical | EoE | Recruiting | 2417 | EFS |
| NCT05664978 | Preclinical | PAH | Recruiting | 1034 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Doxacagene | Sanofi | Approved | PSMA | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| GMA-729 | Genmab | Phase 2 | BCL-2 |